[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617010":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":16,"responsibleParty":34,"collaborators":36,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":7,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Clinical Hub for Interventional Research (CHOIR)","OTHER_GOV",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Mark Polizzotto Professor","CONTACT","+61000000000","mosaic.jcsmr@anu.edu.au",{"name":15,"role":11,"phone":7,"phoneExt":12,"email":13},"Jun Yen Ng Dr",[17],{"facility":18,"status":19,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Canberra Health Services","RECRUITING","Canberra","Australian Capital Territory","2605","Australia","AU",{"type":26,"coordinates":27},"Point",[28,29],149.12807,-35.28346,{"lat":29,"lon":28},[32,33],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":15,"role":11,"phone":7,"phoneExt":12,"email":13},{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[37,40,42,44],{"name":38,"class":39},"Medical Research Future Fund","OTHER",{"name":41,"class":39},"Australian National University",{"name":43,"class":39},"University of Auckland, New Zealand",{"name":45,"class":39},"The Canberra Hospital","100617010","chapter-clonal-haematopoiesis-assessment-prevention-treatment-and-research-100617010",false,"NCT07313059","CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research","Prospective Clinical Evaluation of Incidence, Outcomes and Individuals Experiences Following Diagnosis of Clonal Haematopoiesis in a Dedicated Research Clinic","CHAPTER","Inclusion Criteria:\n\n1. Aged 55 years and above\n2. Confirmed CH or possible CH, with possible CH defined by:\n\n   a. Persistent, non-severe cytopenia, characterised by one or more of the following, present on at least 2 occasions, at least 4 months apart (WHO criteria): i. Absolute neutrophil count (ANC) \\\u003C 1.8 x 109\u002FL ii. Haemoglobin (Hb) \\\u003C 120 g\u002FL in females, \\\u003C 130 g\u002FL in males iii. Platelet count \\\u003C 150 x 109\u002FL\n3. Provision of written informed consent prior to any study-related assessments or procedures being carried out.\n\nExclusion Criteria:\n\n1. Severe cytopenia as defined by one or more of the following:\n\n   1. ANC \\\u003C 0.5 x109\u002FL\n   2. Hb \\\u003C 80 g\u002FL\n   3. Platelet count \\\u003C 50 x 109\u002FL\n2. Multilineage cytopenias:\n\n   a. Marked trilineage cytopenia with all the following present: i. ANC \\\u003C 1.0 x 109\u002FL AND ii. Hb \\\u003C 110 g\u002FL AND iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   b. Marked bilineage cytopenia, with two or more of the following present: i. ANC \\\u003C 1.0 x 109\u002FL ii. Hb \\\u003C 110 g\u002FL iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   Note: People with possible CH, with the above characteristics will be excluded from referral to the CH clinic and will instead have urgent investigation as an inpatient or in the haematology clinic. However, if no definite cause for cytopenia is identified, including CH, then individuals may be referred for CH screening at the CH clinic the discretion of the study PI","ALL","55 Years",{"count":57,"type":58},100,"ESTIMATED","5 Years","OBSERVATIONAL","People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study.\n\nIndividuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH.\n\nResearchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes.\n\nThe information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia.\n\nParticipants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.",[63,64,65],"Clonal Hematopoiesis","CCUS Clonal Cytopenia of Undetermined Significance","Hematologic Disease and Disorders",[63,67,68],"CH","CCUS","2026-05-11",{"date":71,"type":72},"2026-05-13","ACTUAL",{"date":74,"type":72},"2026-03-20",{"date":76,"type":58},"2033-11",{"name":5,"class":6},1]